Inogen, Inc. (NASDAQ:INGN) Short Interest Update

Inogen, Inc. (NASDAQ:INGN) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 665,900 shares, a decline of 16.6% from the January 31st total of 798,600 shares. Based on an average trading volume of 246,200 shares, the short-interest ratio is currently 2.7 days. Approximately 3.2% of the company’s shares are short sold.

Analysts Set New Price Targets

A number of brokerages have weighed in on INGN. StockNews.com lowered Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research report on Wednesday, February 26th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PharVision Advisers LLC purchased a new position in shares of Inogen in the 4th quarter worth about $173,000. Squarepoint Ops LLC acquired a new stake in Inogen during the 4th quarter worth approximately $424,000. State of Wyoming raised its holdings in Inogen by 520.3% in the fourth quarter. State of Wyoming now owns 20,229 shares of the medical technology company’s stock valued at $186,000 after buying an additional 16,968 shares during the period. Millennium Management LLC lifted its position in Inogen by 162.5% during the fourth quarter. Millennium Management LLC now owns 143,653 shares of the medical technology company’s stock valued at $1,317,000 after buying an additional 88,924 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in Inogen by 4.4% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 303,522 shares of the medical technology company’s stock worth $2,783,000 after buying an additional 12,654 shares during the period. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Price Performance

INGN stock traded up $0.17 on Wednesday, hitting $8.20. 294,093 shares of the company were exchanged, compared to its average volume of 314,666. The stock has a market capitalization of $195.36 million, a price-to-earnings ratio of -3.62 and a beta of 1.02. Inogen has a twelve month low of $6.14 and a twelve month high of $13.33. The business’s fifty day moving average is $10.16 and its two-hundred day moving average is $10.11.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.